| Description | KIAA1549 Human Pre-designed siRNA Set A contains three designed siRNAs for KIAA1549 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components KIAA1549 siRNA-1: 5 nmol (HPLC) KIAA1549 siRNA-2: 5 nmol (HPLC) KIAA1549 siRNA-3: 5 nmol (HPLC) siRNA KIAA1549 Human Pre-designed siRNA Set A contains three designed siRNAs for KIAA1549 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components KIAA1549 siRNA-1: 5 nmol (HPLC) KIAA1549 siRNA-2: 5 nmol (HPLC) KIAA1549 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description:HSPD1, also known as HSP60, is a member of the chaperonin family. HSPD1 may function as a signaling molecule in the innate immune system. This protein is essential for the folding and assembly of newly Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description:HSPD1, also known as HSP60, is a member of the chaperonin family. HSPD1 may function as a signaling molecule in the innate immune system. This protein is essential for the folding and assembly of newly imported proteins in the mitochondria. It may also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix. HSPD1 gene is adjacent to a related family member and the region between the 2 genes functions as a bidirectional promoter. Several pseudogenes have been associated with this gene. Mutations associated with this gene cause autosomal recessive spastic paraplegia 13. Defects in HSPD1 are a cause of spastic paraplegia autosomal dominant type 13 (SPG13). Spastic paraplegia is a degenerative spinal cord disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Defects in HSPD1 are the cause of leukodystrophy hypomyelinating type 4 (HLD4); also called mitochondrial HSP60 chaperonopathy or MitCHAP-60 disease. HLD4 is a severe autosomal recessive hypomyelinating leukodystrophy. HSPD1 is clinically characterized by infantile-onset rotary nystagmus, progressive spastic paraplegia, neurologic regression, motor impairment, profound mental retardation. Death usually occurs within the first two decades of life... Read More | Purity>95% SDS-PAGE. Protein Content and Purity (typically = 95%) determined by reducing and Non-reducing SDS-PAGE, UV spectroscopy at 280 nm.Additional sequence informationThis product is for the mature full length protein. The signal peptide is not included.FunctionCytokine with a wide variety Purity>95% SDS-PAGE. Protein Content and Purity (typically = 95%) determined by reducing and Non-reducing SDS-PAGE, UV spectroscopy at 280 nm.Additional sequence informationThis product is for the mature full length protein. The signal peptide is not included.FunctionCytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.Post-translational:N- and O-glycosylated... Read More | Purity≥95% SDS-PAGE.Endotoxin level<0.1 EU/µgFunctionInhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate Purity≥95% SDS-PAGE.Endotoxin level<0.1 EU/µgFunctionInhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.Post-translationalO-glycosylated... Read More |